R&D channel feed

GW Phar­ma’s ral­ly rolls on as cannabi­noid drug scores again in PhI­II Epid­i­olex an­ti-con­vul­sive study

9 years ago

Scor­ing the 5 top phase III drugs in the glob­al pipeline

9 years ago
Pharma

Gary Glick gets $27M to leap back in­to im­muno-on­col­o­gy R&D with No­var­tis, At­las and Abing­worth in his cor­ner

9 years ago
People

An­ti­fun­gal play­er F2G banks $60M, eyes IPO in lead­up to a PhI­II tri­al

9 years ago
Financing

Sean Park­er finds a big role to play in can­cer R&D: The dis­rup­tive bil­lion­aire

9 years ago
People

Cir­cas­sia shares crum­ble as PhI­II flop blights the sec­tor once again

9 years ago

Epizyme says it’s ex­cit­ed by PhII da­ta, but there’s plen­ty to fret about

9 years ago
First page Previous page 331332333334
A service from the Financial Times